Long-Acting Lipoglycopeptides in Orthopedic and Cardiovascular Device-Associated Infections: Outcomes According to Source-Control Strategy in a Multicenter Day-Hospital Cohort
Background: Long-acting lipoglycopeptides (LALs) can simplify prolonged anti-Gram-positive therapy, but evidence in infections involving orthopedic or cardiovascular prosthetic material remains limited, particularly in relation to surgical source control. Methods: We performed a post hoc secondary analysis of a previously published multicenter day-hospital cohort. Adults with orthopedic or cardiovascular prosthetic material and a deep-seated or device-associated infection treated with at least one dose of dalbavancin and/or oritavancin between January 2020 and December 2025 were included; patients with an unrelated acute bacterial skin and skin-structure infection were excluded. Clinical outcomes were examined according to eventual device management (retention versus removal; total versus partial explantation). Results: Forty-six patients were included; median age was 72.3 years (IQR 60.4–79.1) and median Charlson Comorbidity Index was 4 (IQR 2.2–6.0). Prosthetic joint infection accounted for 25/46 cases (54.3%). Forty-five patients received a dalbavancin-containing regimen and 31/46 (67.4%) received LAL monotherapy. Clinical success at last available follow-up was 87.0% (40/46; exact 95% CI 73.7–95.1). Among the 40 patients with a classified source-control strategy and an infection involving the recorded device, success was 88.9% with retention (16/18) and 86.4% with removal (19/22); the exact conditional odds ratio was 1.26 (95% CI 0.13–16.79; Fisher p = 1.000). After removal, success was 89.5% after total explantation (17/19) and 66.7% after partial removal (2/3). C-reactive protein fell from 3.65 to 0.91 mg/dL (p < 0.001). Adverse drug events were mild and infrequent (2/40). Conclusions: In this post hoc, uncontrolled device-focused analysis, LAL-based day-hospital management was feasible with favorable observed outcomes. The source-control comparison was imprecise and cannot support superiority of retention or removal; it should be interpreted as descriptive and hypothesis-generating. Follow-up duration was not standardized, so durable cure could not be assessed.
Authors
- Bianca Catania (ORCID: https://orcid.org/0000-0002-7298-9140)
- Andrea De Vito (ORCID: https://orcid.org/0000-0002-8265-5400)
- Fabrizio Pulvirenti
- Chiara Iaria (ORCID: https://orcid.org/0000-0002-5477-9887)
- Alessandro Geremia
- Nicholas Geremia (ORCID: https://orcid.org/0000-0001-7988-5419)
- Laura Santoro
- Emmanuele Venanzi Rullo (ORCID: https://orcid.org/0000-0001-8273-5382)
- Eugenia Pistarà
- Antonio Albanese (ORCID: https://orcid.org/0009-0005-0057-3487)
- Giuseppe Pipitone (ORCID: https://orcid.org/0000-0002-3408-4877)
- Giuseppe Nunnari (ORCID: https://orcid.org/0000-0002-8113-8452)
- Carmelo Iacobello
- Giordano Madeddu (ORCID: https://orcid.org/0000-0001-6099-2273)
- Andrea Marıno (ORCID: https://orcid.org/0000-0002-5650-6911)
- Bruno Santi Cacopardo (ORCID: https://orcid.org/0000-0002-7465-0714)
- Alessandro Franzò (ORCID: https://orcid.org/0009-0000-9168-3246)
- Barbara Bellocchi
- Rosa Manuele
- Serena Spampinato (ORCID: https://orcid.org/0009-0003-0149-2078)
- A Buzzi
- Paolo Italia
Institutions
- University of Messina (IT)
- University of Sassari (IT)
- University of Catania (IT)
- Ospedale Garibaldi (IT)
- Ospedale Cannizzaro (IT)
- Ospedale dell' Angelo (IT)
- Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco" (IT)
- Ospedale Civile di Venezia (IT)
- Ospedale Civile di Vittorio Veneto (IT)
- Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte (IT)
Publication Details
- Journal
- Antibiotics
- Published
- 2026-11-18
- DOI
- https://doi.org/10.3390/antibiotics15111150
- Primary Topic
- Orthopedic Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00